CA3203202A1 - Nanobody to glycoprotein vi - Google Patents
Nanobody to glycoprotein viInfo
- Publication number
- CA3203202A1 CA3203202A1 CA3203202A CA3203202A CA3203202A1 CA 3203202 A1 CA3203202 A1 CA 3203202A1 CA 3203202 A CA3203202 A CA 3203202A CA 3203202 A CA3203202 A CA 3203202A CA 3203202 A1 CA3203202 A1 CA 3203202A1
- Authority
- CA
- Canada
- Prior art keywords
- nanobody
- gpvi
- binding
- antigen binding
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2020602.5A GB202020602D0 (en) | 2020-12-24 | 2020-12-24 | Nanobody |
| GB2020602.5 | 2020-12-24 | ||
| PCT/EP2021/087129 WO2022136457A1 (en) | 2020-12-24 | 2021-12-21 | Nanobody to glycoprotein vi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3203202A1 true CA3203202A1 (en) | 2022-06-30 |
Family
ID=74532190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3203202A Pending CA3203202A1 (en) | 2020-12-24 | 2021-12-21 | Nanobody to glycoprotein vi |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240067721A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4267624A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024500946A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117043191A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3203202A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB202020602D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022136457A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026019685A1 (en) * | 2024-07-17 | 2026-01-22 | Harpoon Therapeutics, Inc. | Her2 targeting trispecific protein for treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130543D0 (en) * | 2001-12-20 | 2002-02-06 | Univ Cambridge Tech | Human antibodies and their use |
| US20090130021A1 (en) * | 2002-06-07 | 2009-05-21 | Gotz Munch | Methods, products and uses involving platelets and/or the vasculature |
| WO2007091719A1 (ja) * | 2006-02-07 | 2007-08-16 | Mochida Pharmaceutical Co., Ltd. | 抗gpvi抗体の併用療法及び新規医薬用途 |
| EP1916259A1 (en) * | 2006-10-26 | 2008-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-glycoprotein VI SCFV fragment for treatment of thrombosis |
| JP5843783B2 (ja) * | 2009-12-18 | 2016-01-13 | サノフイ | GPVIに対する新規アンタゴニスト抗体および該抗体のFabフラグメントならびにこれらの使用 |
-
2020
- 2020-12-24 GB GBGB2020602.5A patent/GB202020602D0/en not_active Ceased
-
2021
- 2021-12-21 WO PCT/EP2021/087129 patent/WO2022136457A1/en not_active Ceased
- 2021-12-21 CN CN202180094483.4A patent/CN117043191A/zh active Pending
- 2021-12-21 US US18/269,308 patent/US20240067721A1/en active Pending
- 2021-12-21 EP EP21844966.8A patent/EP4267624A1/en active Pending
- 2021-12-21 JP JP2023538767A patent/JP2024500946A/ja active Pending
- 2021-12-21 CA CA3203202A patent/CA3203202A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117043191A (zh) | 2023-11-10 |
| EP4267624A1 (en) | 2023-11-01 |
| WO2022136457A1 (en) | 2022-06-30 |
| US20240067721A1 (en) | 2024-02-29 |
| JP2024500946A (ja) | 2024-01-10 |
| GB202020602D0 (en) | 2021-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7668256B2 (ja) | Dll3及びcd3に結合する二重特異性抗体構築物 | |
| KR102700015B1 (ko) | 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물 | |
| KR102944460B1 (ko) | Cldn18.2 및 cd3에 대한 항체 작제물 | |
| KR102914586B1 (ko) | 메소텔린 및 cd3에 결합하는 이중특이적 항체 작제물 | |
| JP6959011B2 (ja) | Bcmaおよびcd3に対する二重特異性を有するt細胞エンゲージ抗体コンストラクト | |
| KR102735615B1 (ko) | Egfrviii 및 cd3에 결합하는 이중특이적 항체 작제물 | |
| AU2016250023B2 (en) | Bispecific antibody constructs for CDH3 and CD3 | |
| JP7785450B2 (ja) | Muc17及びcd3に向けられる二重特異性抗体コンストラクト | |
| KR20260028110A (ko) | 이중특이성 t 세포 맞물림 항체 작제물 | |
| RS66465B1 (sr) | Inhibitorna monoklonska antitela protiv faktora xii/xiia i njihove upotrebe | |
| US12617863B2 (en) | Humanized anti-glycoprotein Ib alpha (GPIbalpha) antibodies | |
| AU2019338955B2 (en) | Bispecific antibody targeting IL-1R1 and NLRP3 | |
| US20210214435A1 (en) | Antibodies targeting glycoprotein vi | |
| US20240067721A1 (en) | Nanobody to glycoprotein vi | |
| CA3188566A1 (en) | Coagulation factor xi (fxi) binding protein | |
| WO2020243228A1 (en) | Antibodies to polyphosphate decrease fibrosis | |
| US20200048333A1 (en) | Antigen-binding domains of the monoclonal anti-collagen i antibody | |
| US20250051452A1 (en) | Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering | |
| CN120173111B (zh) | 一种抗血小板GPIb-IX抗体及其应用 | |
| JP2025533434A (ja) | 二重特異性分子安定化組成物 | |
| HK40130468A (en) | Low ph pharmaceutical composition comprising t cell engaging antibody constructs | |
| EA046884B1 (ru) | Фармацевтическая композиция, содержащая конструкции на основе биспецифического антитела, обеспечивающая улучшенное хранение и введение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241209 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260428 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260622 |